UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2022
Commission File Number: 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
CONTENTS
On August 25, 2022, Evogene Ltd., or Evogene, issued a press release announcing that it regained compliance
with Nasdaq minimum closing bid price rule. A copy of the press release is attached hereto as
Exhibit 99.1 and incorporated herein by
reference.
This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration
statements on Form F-3 (File No. 333-253300) and on Form S-8 (File Nos. 333-193788,
333-201443, 333-203856 and 333-259215) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: August 25, 2022
|
|
EVOGENE LTD.
(Registrant)
By: /s/ Yaron Eldad
——————————————
Yaron Eldad
Chief Financial Officer
|